Drugs / B Lymphocyte Stimulator
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00024934 | Oct 2001 → Aug 2004 | selective IgA deficiency disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B Lymphocyte Stimulator | “B-Lymphocyte Stimulator (BLyS)” NCT00024934 ↗ |
| Known as | BLyS | “B-Lymphocyte Stimulator (BLyS)” NCT00024934 ↗ |
| Action | Activate | “BLyS increases B cell number, Ig production, antigen-specific immunoglobulin response, and induces production of secretory IgA.” NCT00024934 ↗ |
| Modality | Protein / enzyme biologic | “member of the tumor necrosis factor (TNF) superfamily of cytokines” NCT00024934 ↗ |
| Route | Subcutaneous | “B-Lymphocyte Stimulator (BLyS) Administered Subcutaneously” NCT00024934 ↗ |